The Mechanisms and Role of HIF-PHIs in Patients with CKD and Anemia: Advances in the Therapeutic Landscape – Tweetorial #1 Evaluation (ID: i784-2) Survey

Question Title

* 1. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 2. How many patients with CKD and anemia do you manage ?

1 to 25

26 to 50

51 to 100

100+

I am not directly involved in patient care

Question Title

* 3. Please select the option that best describes your practice setting.

Academic medical center

Community hospital or medical center

Private practice

Managed Care

Research

Pharmaceutical industry

Question Title

* 4. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

Question Title

* 5. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 6. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please explain)

Question Title

* 7. Please rate your level of agreement by checking the appropriate rating

After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Describe the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy.	Describe the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Strongly agree	Describe the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Agree	Describe the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Neutral	Describe the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Disagree	Describe the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy. Strongly disagree
Explain the pathophysiologic processes underlying anemia associated with CKD, including potential therapeutic targets	Explain the pathophysiologic processes underlying anemia associated with CKD, including potential therapeutic targets Strongly agree	Explain the pathophysiologic processes underlying anemia associated with CKD, including potential therapeutic targets Agree	Explain the pathophysiologic processes underlying anemia associated with CKD, including potential therapeutic targets Neutral	Explain the pathophysiologic processes underlying anemia associated with CKD, including potential therapeutic targets Disagree	Explain the pathophysiologic processes underlying anemia associated with CKD, including potential therapeutic targets Strongly disagree

Question Title

* 8. Please rate your level of agreement by checking the appropriate rating.

Martha Guladi, MD, MS, FACC, FAHA, FASPC, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.

Daniel Coyne, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 10. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 11. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 12. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with CKD and anemia do you manage ?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 5. Which of the following best describes the impact of this activity on your performance?

Question Title

* 6. What barriers do you see to making changes in your practice?

Question Title

* 7. Please rate your level of agreement by checking the appropriate ratingAfter participating in today’s activity, I am now able to:

Question Title

* 8. Please rate your level of agreement by checking the appropriate rating. Martha Guladi, MD, MS, FACC, FAHA, FASPC, effectively:

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating. Daniel Coyne, MD, effectively:

Question Title

* 10. The content presented:

Question Title

* 11. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 12. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 13. If you indicated that you perceived commercial bias or influence, please describe:

* 7. Please rate your level of agreement by checking the appropriate rating

After participating in today’s activity, I am now able to:

* 8. Please rate your level of agreement by checking the appropriate rating.

Martha Guladi, MD, MS, FACC, FAHA, FASPC, effectively:

* 9. Please rate your level of agreement by checking the appropriate rating.

Daniel Coyne, MD, effectively: